Jaypirca® (Pirtobrutinib) Yemejwe mu Bushinwa mu kuvura Leukemia idakira cyangwa idafite ubushobozi bwo kuvura indwara ya Lymphocytic Leukemia cyangwa Lymphoma ntoya y’imitsi.

Mu ntangiriro za Werurwe, Ikigo cy’Igihugu gishinzwe Ibikoresho by’Ubuvuzi cyemeje Jaypirca® (pirtobrutinib) ku barwayi bakuru barwaye kanseri y’urukende idakira (CLL) cyangwa lymphoma ntoya (SLL) bahawe nibura ubuvuzi bumwe mbere, harimo n’umuti ubuza Bruton's tyrosine kinase (BTK).

Pirtobrutinib ni umuti ugabanya cyane kinase inhibitor ukoresha uburyo bushya bwo gufatana butari covalent kugira ngo wongere inyungu zo kwibanda ku nzira ya BTK ku barwayi ba CLL/SLL bavuwe mbere hakoreshejwe umuti ugabanya covalent BTK inhibitor (ibrutinib, acalabrutinib, cyangwa zanubrutinib). Pirtobrutinib yemejwe na FDA yo muri Amerika muri Mutarama 2023 nk'umuti ugabanya covalent BTK inhibitor. Mu Ukwakira 2024, pirtobrutinib yemejwe mu Bushinwa nk'umuti umwe wo kuvura abarwayi bakuru bafite lymphoma ya relaxed cyangwa refractory mantle cell lymphoma (MCL) bamaze guhabwa nibura ubuvuzi bubiri bwabanje, harimo n'umuti ugabanya Bruton's tyrosine kinase (BTK).

Kwemezwa kw'iki kimenyetso gishya bishingiye ku byavuye mu bushakashatsi mpuzamahanga, bwakozwe mu bigo byinshi, kandi butateguwe, bwakozwe ku buryo butazwi, bwakozwe ku nshuro ya 3 na BRUIN CLL 321. BRUIN CLL 321 ni bwo bushakashatsi bwa mbere ku isi bwakozwe ku barwayi ba CLL/SLL bari baravuwe mbere hakoreshejwe umuti ugabanya BTK (cBTKi). Ubu bushakashatsi bwakorewe ku barwayi 238, busuzuma imikorere n'umutekano wa pirtobrutinib monotherapy ugereranije n'uburyo umushakashatsi yahisemo IdelaR (idelalisib plus rituximab) cyangwa BR (bendamustine plus rituximab). Ibisubizo byagaragaje ko pirtobrutinib yagabanyije cyane uburyo bwo kubaho budafite ingaruka mbi (PFS) ugereranije n'uburyo umushakashatsi yahisemo (amezi 14.0 ugereranije n'amezi 8.7; igipimo cy'ibyago [HR] = 0.54). Byongeye kandi, igipimo cyo guhagarika imiti bitewe n’ingaruka mbi zijyanye n’ubuvuzi cyari gito kuri pirtobrutinib (5.2% ugereranije na 21.1%), birushaho gushyigikira imikorere yayo n’inyungu zayo zo kwihanganira abarwayi bavuwe mbere hakoreshejwe umuti wa BTK ugabanya ubukana.

Twandikire kugira ngo utangire urugendo rwawe rw'ibyiringiro

Ishami Mpuzamahanga ry’Ibitaro bya Oncology byo mu Karere k’Amajyepfo rya Beijing ryiyemeje guha abarwayi bo ku isi uburyo bwo kuvura kanseri bugezweho. Niba wowe cyangwa umwe mu bagize umuryango wawe arwaye kanseri kandi akaba atarakira neza ubuvuzi busanzwe, itsinda ryacu Mpuzamahanga ryita ku barwayi ryiteguye kuguha amakuru arambuye na gahunda z’ubuvuzi bwihariye.

Twandikire ukoresheje inzira zikurikira kugira ngo umenye byinshi ku bijyanye n'uburyo bwo kuvura kanseri:

- Terefone: 400-880-3716

- WeChat: 17801183037

-   Email: 100085_010@163.com or myimmnet@163.com (Emails are welcome, and we will respond promptly)

Ishami Mpuzamahanga ry’Ibitaro bya Oncology byo mu Karere k’Amajyepfo ka Beijing ryiteguye gufatanya nawe mu kurwanya kanseri. Aho waba uri hose ku isi, twiyemeje kuguha ubufasha bw’ubuvuzi bw’umwuga n’ubuvuzi bw’impuhwe.

Take the first step towards overcoming your illness. Call us at 400-880-3716 or contact us via WeChat at 17801183037 today. You can also email us at 100085_010@163.com or myimmnet@163.com to schedule a one-on-one consultation with our team of experts.